Tavilermide (MIM-D3) (Synonyms: MIM-D3) |
Catalog No.GC31676 |
Le tavilermide (MIM-D3) est un agoniste partiel sélectif de TrkA, ou un mimétique du facteur de croissance nerveuse (NGF).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 263251-78-1
Sample solution is provided at 25 µL, 10mM.
Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF[1].
[1]. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85.
Average Rating: 5
(Based on Reviews and 37 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *